ECSP13013036A - Alfa glucosidasa ácida modificada con procesamiento acelerado - Google Patents

Alfa glucosidasa ácida modificada con procesamiento acelerado

Info

Publication number
ECSP13013036A
ECSP13013036A ECSP13013036A ECSP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A
Authority
EC
Ecuador
Prior art keywords
accelerated processing
modified acid
alfa
glucosidase modified
alfa glucosidase
Prior art date
Application number
Other languages
English (en)
Inventor
William M Canfield
Rodney J Moreland
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013036(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of ECSP13013036A publication Critical patent/ECSP13013036A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporciona un polipéptido de alfa-glucosidasa ácida humana modificada, así como métodos para producir y usar la alfa-glucosidasa ácida humana modificada para tratar una glucogenosis.
ECSP13013036 2011-04-22 2013-11-21 Alfa glucosidasa ácida modificada con procesamiento acelerado ECSP13013036A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
ECSP13013036A true ECSP13013036A (es) 2015-04-30

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013036 ECSP13013036A (es) 2011-04-22 2013-11-21 Alfa glucosidasa ácida modificada con procesamiento acelerado

Country Status (24)

Country Link
US (1) US20140186326A1 (es)
EP (1) EP2699676A1 (es)
JP (2) JP2014513952A (es)
KR (1) KR20140037082A (es)
CN (1) CN103797115A (es)
AU (1) AU2012245280A1 (es)
BR (1) BR112013026976A2 (es)
CA (1) CA2833371A1 (es)
CL (1) CL2013003010A1 (es)
CO (1) CO6811810A2 (es)
CR (1) CR20130555A (es)
EC (1) ECSP13013036A (es)
GT (1) GT201300252A (es)
IL (1) IL228871A0 (es)
MA (1) MA35125B1 (es)
MX (1) MX2013012345A (es)
NI (1) NI201300110A (es)
PE (1) PE20140617A1 (es)
PH (1) PH12013502149A1 (es)
RU (1) RU2013151875A (es)
SG (2) SG194486A1 (es)
TN (1) TN2013000427A1 (es)
WO (1) WO2012145644A1 (es)
ZA (1) ZA201307696B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901978A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
PE20170906A1 (es) 2014-09-30 2017-07-12 Amicus Therapeutics Inc Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados
CN108474788A (zh) * 2015-11-06 2018-08-31 生物马林药物股份有限公司 用于检测中和溶酶体酶的摄取的抗体或其它因子的基于细胞的测定
MX394968B (es) 2015-12-30 2025-03-24 Amicus Therapeutics Inc Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
WO2017173060A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
MX2018011951A (es) 2016-03-30 2019-02-13 Amicus Therapeutics Inc Metodo para seleccionar proteinas recombinantes ricas en m6p.
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
CN110050063B (zh) 2016-09-12 2023-11-03 吉尼松公司 酸性α-葡萄糖苷酶变体及其用途
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
AU2018270925B2 (en) 2017-05-15 2025-02-20 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
WO2018226861A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
KR20250140631A (ko) 2018-05-17 2025-09-25 리제너론 파마슈티칼스 인코포레이티드 항-cd63 항체, 콘쥬게이트, 및 이의 용도
WO2021005176A1 (en) 2019-07-09 2021-01-14 Genethon Treatment of glycogen storage disease (gsd)
PH12022551229A1 (en) * 2019-11-19 2023-07-31 Asklepios Biopharmaceutical Inc Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US20030007963A1 (en) * 1998-12-07 2003-01-09 Van Bree Johannes B. M. M. Treatment of pompe's disease
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
JP2002522509A (ja) 1997-10-29 2002-07-23 ジェンザイム・コーポレイション リソソーム貯蔵疾患治療組成物および方法
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20040248262A1 (en) * 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
HUE036449T2 (hu) 2003-06-24 2018-07-30 Genzyme Corp Új béta-aktin és RPS21 promóterek és alkalmazásaik
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
AU2012245280A1 (en) 2013-11-07
CR20130555A (es) 2013-12-09
PE20140617A1 (es) 2014-05-28
SG10201605874TA (en) 2016-09-29
CL2013003010A1 (es) 2014-03-07
US20140186326A1 (en) 2014-07-03
EP2699676A1 (en) 2014-02-26
JP2017035091A (ja) 2017-02-16
CN103797115A (zh) 2014-05-14
KR20140037082A (ko) 2014-03-26
MX2013012345A (es) 2015-05-07
WO2012145644A1 (en) 2012-10-26
IL228871A0 (en) 2013-12-31
JP2014513952A (ja) 2014-06-19
NI201300110A (es) 2014-02-28
GT201300252A (es) 2015-02-09
CA2833371A1 (en) 2012-10-26
RU2013151875A (ru) 2015-05-27
ZA201307696B (en) 2014-07-30
MA35125B1 (fr) 2014-05-02
SG194486A1 (en) 2013-12-30
TN2013000427A1 (en) 2015-03-30
PH12013502149A1 (en) 2019-09-02
CO6811810A2 (es) 2013-12-16
BR112013026976A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
ECSP13013036A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
UY34577A (es) Método para estabilizar fibra de lignina y su posterior conversión en fibra de carbono
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
HUE039816T2 (hu) Lignocellulózos biomassza egylépcsõs autohidrolízis és C5 kikerülésével történõ enzimatikus hidrolízis és poszthidrolízis alkalmazásával történõ feldolgozásának eljárásai
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
IL222824B (en) Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
UA110813C2 (uk) Лікування ліподистрофії
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
BR112015008111A2 (pt) célula de levedura geneticamente modificada, e , método para a produção de 3hp.
PL2865038T3 (pl) Elektroda dwubiegunowa i sposób jej wytwarzania
MX2018014043A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AR085793A1 (es) Metodo para producir una fibra de lignina
MX2016003737A (es) Microorganismo recombinante para la mejora de produccion de productos quimicos finos.
UY33992A (es) Métodos para modificar la biosintesis de la lignina y mejorar la digestibilidad
AR093986A1 (es) Cuerpos de carbono ferromagneticos y proceso de produccion
PH12016501094A1 (en) Recombinant microorganism for improved production of fine chemicals
IN2014DN07958A (es)
MY183321A (en) Microorganism producing o-acetyl-homoserine and method for producing o-acetylhomoserine using the same
EA201590718A1 (ru) Способы получения макроциклических депсипептидов с использованием ацетальальдегида и новые промежуточные соединения
BR112013023144A2 (pt) método de tratamento de couro cabeludo
MX2012010382A (es) Modulacion de acuaporinas con relaxina.
CO7200264A2 (es) Fluoruros de fluorpicolinoilo y procesos para su preparación
BR112013030164A2 (pt) pilha de combustível e processo de realização de uma pilha de combustível.
UY34312A (es) Compuesto de benzotiazolona